These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30018024)

  • 21. Calcineurin inhibitors in kidney transplantation: friend or foe?
    Casey MJ; Meier-Kriesche HU
    Curr Opin Nephrol Hypertens; 2011 Nov; 20(6):610-5. PubMed ID: 21885969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors.
    Carreras-Planella L; Juega J; Taco O; Cañas L; Franquesa M; Lauzurica R; Borràs FE
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
    Lin W; Mou L; Tu H; Zhu L; Wang J; Chen J; Hu Y
    J Clin Pharm Ther; 2017 Feb; 42(1):122-124. PubMed ID: 27966241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients.
    Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells.
    Loeschenberger B; Niess L; Würzner R; Schwelberger H; Eder IE; Puhr M; Guenther J; Troppmair J; Rudnicki M; Neuwirt H
    Eur J Immunol; 2018 Feb; 48(2):330-343. PubMed ID: 29143318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monitoring of calcineurin inhibitors induced-nephrotoxicity].
    Kamar N; Rostaing L
    Nephrol Ther; 2008 Jun; 4 Suppl 1():S13-S17. PubMed ID: 18703392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcineurin Inhibitors Downregulate HNF-1β and May Affect the Outcome of HNF1B Patients After Renal Transplantation.
    Faguer S; Esposito L; Casemayou A; Pirson Y; Decramer S; Cartery C; Hazzan M; Garrigue V; Roussey G; Cointault O; Ho T; Merville P; Devuyst O; Gourdy P; Chassaing N; Bascands JL; Kamar N; Schanstra JP; Rostaing L; Chauveau D
    Transplantation; 2016 Sep; 100(9):1970-8. PubMed ID: 26555949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
    Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up.
    Heeg MH; Mueller GA; Bramlage C; Homayounfar K; Muehlhausen J; Leha A; Koziolek MJ
    Transplant Proc; 2013; 45(1):142-7. PubMed ID: 23375288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of calcineurin inhibitors on neutrophil gelatinase-associated lipocalin and fibroblast growth factor 23 in long-term kidney transplant patients.
    Bleskestad IH; Thorsen IS; Jonsson G; Skadberg Ø; Gøransson LG
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28523792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altitude and arteriolar hyalinosis after kidney transplantation.
    Cippà PE; Grebe SO; Fehr T; Wüthrich RP; Mueller TF
    Nephrology (Carlton); 2016 Sep; 21(9):782-4. PubMed ID: 26823025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.
    Zanchi C; Macconi D; Trionfini P; Tomasoni S; Rottoli D; Locatelli M; Rudnicki M; Vandesompele J; Mestdagh P; Remuzzi G; Benigni A; Zoja C
    Diabetologia; 2017 Jun; 60(6):1114-1125. PubMed ID: 28364255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants.
    Bicknell GR; Williams ST; Shaw JA; Pringle JH; Furness PN; Nicholson ML
    Br J Surg; 2000 Nov; 87(11):1569-75. PubMed ID: 11091247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.
    Pallet N; Djamali A; Legendre C
    Pharmacol Res; 2011 Jul; 64(1):25-30. PubMed ID: 21473913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors].
    Snanoudj R; Rabant M; Royal V; Pallet N; Noël LH; Legendre C
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S365-70. PubMed ID: 20129447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
    Boswell A; Evans L; Rigg K; Shehata M
    Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis.
    Hermert D; Martin IV; Reiss LK; Liu X; Breitkopf DM; Reimer KC; Alidousty C; Rauen T; Floege J; Ostendorf T; Weiskirchen R; Raffetseder U
    Kidney Int; 2020 Apr; 97(4):741-752. PubMed ID: 32061437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation.
    Gooch JL; Barnes JL; Garcia S; Abboud HE
    Am J Physiol Renal Physiol; 2003 Jan; 284(1):F144-54. PubMed ID: 12388427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.